MedTrace Logo

Engineered Dendritic Cell Vaccines for Multiple Myeloma

NCT06435910 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

Conditions

  • Multiple Myeloma or Plasmacytoma

Interventions

BIOLOGICAL

DC vaccines

Antigen-presenting and immune modifying DCvacs to treat MM

Sponsors & Collaborators

  • The No.2 Clinical Hospital of the Ministry of Health

    collaborator UNKNOWN

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-11
Primary Completion
2027-07-11
Completion
2027-12-31

Countries

  • China
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435910 on ClinicalTrials.gov